Beam Therapeutics reports early BEAM-301 Phase 1/2 results in GSDIa, including 15-hour controlled fasting, reduced starch dependence and serious adverse events.
Written By: Kirti Kumbhar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Beam Therapeutics has reported initial clinical findings from its Phase 1/2 trial of BEAM-301, an investigational in vivo base-editing therapy designed to correct the R83C variant associated with glycogen storage disease type Ia (GSDIa). The October 27, 2026, data update showed improved fasting tolerance and reduced dependence on starch supplementation in some patients following a single intravenous infusion. However, the findings remain preliminary, with six patients treated across two dose cohorts and serious treatment-related adverse events reported in four patients.
Improved Fasting Tolerance in the 40 mg Cohort
BEAM-301 uses a liver-targeting lipid nanoparticle (LNP) formulation to deliver base-editing reagents designed to correct the R83C mutation, a disease-causing variant associated with severe GSDIa. The condition impairs glucose-6-phosphatase activity, disrupting glucose homeostasis and increasing the risk of fasting hypoglycaemia.
As of the August 17, 2026, data cutoff, six patients had received a single infusion: three at 20 mg and three at 40 mg. Median follow-up across both cohorts was 7.6 months, ranging from 1.9 to 16.6 months. The findings were reported from the ongoing Phase 1/2 trial at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT).
At Day 36, median time to fasting hypoglycaemia (TTH) increased from 2.9 to 4.3 hours in the 20 mg cohort and from 2.5 to 15 hours in the 40 mg cohort. Two of the three patients receiving 40 mg achieved the protocol-defined maximum controlled fasting duration of 15 hours, with blood glucose generally maintained within the euglycaemic range during fasting challenges.
These findings are consistent with improved endogenous glucose regulation following treatment. However, the 15-hour result represents the protocol-defined maximum, not evidence of fasting tolerance beyond that limit. The response was also not uniform: one patient in the 40 mg cohort did not show an increase in TTH at the first post-dose assessment. The company identified elevated body mass index and heterozygosity for R83C as possible contributing factors, although their roles remain uncertain.
Reduced Starch Dependence and Improved Glucose Control
Frequent cornstarch supplementation is central to GSDIa management because it helps maintain blood glucose and prevent fasting hypoglycaemia. BEAM-301 aims to address the underlying genetic defect rather than solely manage its metabolic consequences.
Following treatment, daily starch intake and dosing frequency generally decreased. At baseline, patients in the 20 mg and 40 mg cohorts typically required six to seven and five to six starch doses per day, respectively. Two of the three patients in the 40 mg cohort no longer required starch supplementation at their latest reported assessments, representing a 100% reduction in daily starch requirements.
The October 13 data announcement also reported reductions in prescribed daily starch intake at earlier follow-up assessments. These included reductions of 71% and 92% in two patients in the 40 mg cohort, illustrating the potential clinical relevance of the subsequent observation that both no longer required supplementation at their latest assessments.
Continuous glucose monitoring showed increased time in the euglycaemic range and decreased time in the hyperglycaemic range despite reduced starch intake. Patients generally did not experience increased time in hypoglycaemia, while triglyceride levels remained broadly comparable to baseline at the latest evaluable time point.
Together, these measures provide complementary evidence of improved glucose regulation. Nevertheless, observations in six patients cannot establish how consistently these effects will occur or whether reduced starch requirements will persist over time.
Infusion-Related Reactions Remain a Safety Consideration
All six patients experienced at least one treatment-emergent adverse event considered related to BEAM-301. Four experienced serious treatment-related events, including three Grade 3 infusion-related reactions (IRRs). The company noted that shorter-acting steroid premedication may have contributed to the reactions and reported subsequent modifications to steroid premedication and infusion-rate regimens.
Two other serious adverse events, diarrhoea and rhabdomyolysis, occurred in two patients and resolved. All transaminase elevations resolved without treatment; all were Grade 1 except for one Grade 2 aspartate aminotransferase elevation. Total bilirubin remained within normal limits.
No dose-limiting toxicities, Grade 4 or 5 treatment-emergent adverse events, or treatment discontinuations due to adverse events were reported. These findings are encouraging, but the small cohort cannot reliably characterise uncommon or delayed safety risks.
Dose Escalation and Development Outlook
BEAM-301 is being evaluated in an open-label Phase 1/2 dose-exploration and dose-expansion study assessing safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients homozygous or compound heterozygous for the R83C variant. Enrollment in the 60 mg dose-escalation cohort is underway, and Beam plans to engage the US Food and Drug Administration regarding a potential path to approval.
The initial findings offer early clinical evidence that in vivo base editing may improve fasting tolerance and reduce starch dependence in GSDIa. However, response variability, serious infusion-related reactions, the small patient population and limited follow-up remain important uncertainties. Larger cohorts and longer observation will be needed to establish the durability, safety and extent of clinical benefit.
Reference
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress, Beam Therapeutics, 27 October 2026
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa), ClinicalTrials.gov ID NCT06735755
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.